Utilization of Ultrasound Guided Tissue-directed Cellular Implantation for the Establishment of Biologically Relevant Metastatic Tumor Xenografts
May 25th, 2018
7.9K views
Here, we present a protocol to utilize ultrasound-guided injection of neuroblastoma (NB) and Ewing's sarcoma (ES) cells (established cell lines and patient-derived tumor cells) at biologically relevant sites to create reliable preclinical models for cancer research.
Overview
This article presents a protocol for ultrasound-guided injection of neuroblastoma and Ewing's sarcoma cells into murine models. This technique aims to establish reliable preclinical cancer models that reflect the native tumor microenvironment.
Key Study Components
Area of Science
- Neuroscience
- Oncology
- Preclinical Research
Background
- Patient-derived tumor cells provide a more accurate model for studying cancer.
- Orthotopic xenografts are essential for understanding tumor behavior in a native context.
- Ultrasound guidance allows for precise injection without invasive surgery.
- This method can enhance the reliability of preclinical studies.
Purpose of Study
- To create biologically relevant cancer models for research.
- To investigate tumor evolution and therapeutic responses.
- To facilitate drug discovery through improved preclinical models.
Methods Used
- Ultrasound-guided injection of neuroblastoma cells.
- Injection into the murine adrenal gland.
- Use of patient-derived tumor cells.
- Non-invasive technique to minimize recovery time.
Main Results
- Successful establishment of orthotopic xenografts.
- Demonstrated efficiency and reliability of the method.
- Provided insights into tumor behavior in a native microenvironment.
- Facilitated further studies on therapeutic responses and metastasis.
Conclusions
- The ultrasound-guided injection method is effective for cancer research.
- Patient-derived models improve the relevance of preclinical studies.
- This technique can significantly aid in drug discovery efforts.
Frequently Asked Questions
What is the main advantage of this injection method?
The main advantage is that it allows for patient-derived, tissue-directed, efficient, and reliable orthotopic xenograft models.
How does this method impact cancer research?
It enhances the understanding of tumor evolution and therapeutic responses in a native microenvironment.
Who demonstrates the critical steps in the procedure?
Sahiti Chukkapalli and Tina Thomas demonstrate the procedure.
What types of cells are used in this protocol?
Both established cell lines and patient-derived tumor cells are used.
What is the significance of using patient-derived cells?
They provide a more accurate representation of human tumors, improving the relevance of research findings.
Executive Industry Relevance
Establishing biologically relevant metastatic tumor xenografts using ultrasound-guided, tissue-directed cellular implantation addresses a critical gap in preclinical oncology models by enabling accurate recapitulation of tumor microenvironments and metastatic behavior. This minimally invasive approach enhances predictive confidence for therapeutic response and metastasis studies, supporting risk-adjusted portfolio decisions in oncology drug discovery. The method's reproducibility and translational alignment position it as a strategic asset for enterprise R&D pipelines seeking to de-risk early-stage oncology assets.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables interrogation of therapeutic hypotheses in a native tumor microenvironment.
- Supports functional target validation by modeling metastatic spread and tumor evolution.
- Improves predictive confidence for candidate selection and portfolio triage.
Screening & Assay Development
- Facilitates preparation of validated, orthotopic xenograft models for downstream efficacy testing.
- Provides reproducible, quantitative tumor growth and metastasis readouts via ultrasound and bioluminescence imaging.
- Enables scalable, minimally invasive model establishment for compound evaluation.
Translational & Preclinical Research
- Aligns preclinical models with human disease biology using patient-derived cells and tissue-specific implantation.
- Supports continuity from discovery through preclinical validation by enabling longitudinal assessment of tumor progression and therapeutic response.
- Reduces translational risk by modeling clinically relevant metastatic behavior.
Pipeline & Workflow Integration
This ultrasound-guided xenograft method integrates into the oncology discovery continuum from early target validation through preclinical efficacy studies, enabling robust model generation for lead identification and translational research.
- Discovery Biology: Supports hypothesis testing and mechanistic de-risking by modeling tumor growth in native tissue contexts.
- Screening: Provides standardized, reproducible models with quantitative imaging outputs for compound screening.
- Analytics: Delivers longitudinal tumor size and bioluminescence measurements to compare therapeutic conditions.
- Translational Research: Bridges discovery and preclinical phases by enabling patient-derived, disease-relevant model systems.
- Enterprise Reuse: Offers a platform adaptable to multiple cancer types and cell sources for broad R&D utility.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in oncology models.
- Operational Value: Standardizes and streamlines model establishment with minimal animal morbidity and rapid recovery.
- Strategic Value: Improves go/no-go decision quality and capital efficiency by enhancing model relevance.
- Portfolio Impact: Enables risk-adjusted prioritization and advancement of oncology assets based on translationally aligned data.
Implementation Considerations
- Requires expertise in ultrasound imaging and small animal surgical techniques.
- Needs access to imaging platforms, cell dissociation kits, and bioluminescence analysis infrastructure.
- Demands cross-team standardization for reproducibility and data comparability.
- Adaptable to various cancer types and both established and patient-derived cell lines.
- Limited by the need for specialized training and imaging equipment for precise implantation and monitoring.
Biopharma FAQs
Why does null hypothesis testing matter for ultrasound-guided xenograft validation?
Null hypothesis testing ensures that observed tumor growth and metastasis in ultrasound-guided xenografts are statistically significant and not due to procedural variability, supporting robust target validation and model reliability for drug discovery decisions.
How does independent variable isolation fit the ultrasound-guided implantation workflow?
Isolating variables such as cell type, injection site, and imaging timepoints allows teams to attribute tumor progression and metastasis outcomes directly to experimental interventions, strengthening mechanistic insights and discovery-stage confidence.
What do quantitative dependent variable measurements enable in this xenograft model?
Quantitative measurements of tumor area, volume, and bioluminescence provide objective criteria for model engraftment, therapeutic response, and progression, enabling data-driven advancement and cross-study comparability in preclinical pipelines.
Why are replication requirements critical for cross-functional oncology teams using this model?
Replication ensures that model establishment, tumor growth, and imaging outputs are consistent across operators and studies, facilitating reliable data sharing and collaborative decision-making in multi-disciplinary R&D environments.
Which statistical analysis capabilities are required before implementing ultrasound-guided xenograft studies?
Teams must be equipped to perform statistical comparisons of tumor growth, engraftment rates, and imaging signals to validate model reproducibility and therapeutic effects, supporting rigorous preclinical evaluation and portfolio progression.
